Seven studies reported PFS of individuals with NSCLC stratified by PD-L1 expression, and we found that only individuals with PD-L1-negative expression did not observe a PFS benefit (HR 0.80; 95% CI, 0.63–1.01; p = 0.07), whereas all other individuals with PD-L1-positive expression achieved PFS benefits in atezolizumab-based therapy (Figure S2I and S2). This evidence concerns the gene CD274 and non-small cell lung carcinoma.